Perrigo has completed the acquisition of Omega Pharma. This transaction acts as a massive "commercial accelerator," solving the complex logistical and regulatory barriers inherent in the European pharmacy landscape. By internalizing a sophisticated thirty-five-country distribution network, the group eliminates its dependency on regional third-party agents and secures immediate shelf-space for its expansive US-developed product pipeline. The strategic rationale hinges on the synergy between localized branding expertise and centralized manufacturing scale. While the acquirer provides the industrial backbone and cost-efficiency of a global supplier, the target brings the technical operational depth required to navigate diverse European healthcare systems and consumer preferences.

OMEGA PHARMA, which reported an EBITDA margin of LOGIN in 2014, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 13.3x average currently observed in the Healthcare & Pharma sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.